Immunotherapy approaches are evolving for all types of gynecologic malignancies, including ovarian, cervical, and endometrial cancers.
Maintenance therapy with pazopanib after successful initial chemotherapy for advanced ovarian cancer prolongs time to relapse and PFS compared to placebo, found research presented at ASCO 2013.
In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.
Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.
A survey found that 83% of U.S. oncologists/hematologists reported a chemo drug shortage in the past 6 months, with 94% stating patient care was affected, according to data presented at ASCO 2013.
In men with localized high-risk prostate cancer, androgen-deprivation therapy can be safely reduced from 36 to 18 months, according to research presented at ASCO 2013.
Women with uterine malignancies who took statins and aspirin had an 84% reduction in mortality, while use of statins alone reduced mortality by 45%, according to data presented at ASCO 2013.
MPDL3280A produced durable responses in patients with locally advanced or metastatic lung cancer, melanoma, and renal, colorectal, and gastric cancers, some within days of treatment initiation, found research at ASCO 2013.
Nintedanib in combination with docetaxel significantly prolonged PFS for patients with metastatic NSCLC progressing after first-line chemotherapy regardless of histology, results from the LUME-Lung 1 trial presented at ASCO 2013 have found.
The number of genetic alterations in tumors may predict which patients with breast cancer will benefit from adding everolimus to exemestane, found research presented at ASCO 2013.
VeriStrat test status predicts which patients will see survival benefits from second-line chemotherapy instead of erlotinib therapy for advanced NSCLC, found data presented at ASCO 2013.
Standard-dose radiation therapy is superior to high-dose RT in terms of OS and local-regional control in patients undergoing chemotherapy for stage III NSCLC, found research presented at ASCO 2013.
Imatinib is prolongs PFS but not OS compared to placebo among patients with imatinib- or sunitinib-refractory advanced GIST, according to data presented at ASCO 2013.
Idelalisib (GS-1101) is associated with rapid tumor response in some patients diagnosed with relapsed or treatment-resistant CLL, found research presented at ASCO 2013.
Elderly patients with metastatic pancreatic cancer have shorter OS and receive less chemotherapy, fewer agents compared to younger patients, found research presented at ASCO 2013.
NGS shows promise in identifying solid tumors harboring "actionable" genetic alterations that can be targeted for personalized therapy, according to study results presented at ASCO 2013.
Use of sequential paclitaxel followed by oral fluorinated pyrimidines results in a trend for better disease-free survival in locally advanced gastric cancer, found research presented at ASCO 2013.
African-American women have a high number of breast cancer-related gene mutations and require more access to screening, found results of a study presented at ASCO 2013.
Neither zoledronic acid nor strontium-89 improve OS among patients with castrate-refractory prostate cancer, but Sr89 improves cPFS, according to data presented at ASCO 2013.
For patients with chromosomal rearrangements of the of the ALK gene, crizotinib yields longer PFS and a higher response rate versus standard chemotherapy, found data presented at ASCO 2013.
A case of acquired resistance to crizotinib has been described in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement, according to research presented at ASCO 2013.
Adding ganetespib to docetaxel in salvage therapy prolongs OS compared to docetaxel alone among patients diagnosed with advanced adenocarcinoma lung cancer, research presented at ASCO 2013 has found.
Low-dose weekly paclitaxel and standard every-other-week paclitaxel dosing offer equivalent postsurgical PFS rates among women with higher-risk early-stage breast cancer, according to research presented at ASCO 2013.
Simple vinegar-based visual inspection screenings by primary paramedical health workers reduced cervical cancer mortality by 31% over 15 years, research presented at ASCO 2013 has found.
No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide as Adjuvant Treatment for Breast CancerJune 04, 2013
Single-agent paclitaxel did not show equivalence to doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer in women with zero to three axillary nodes, found data presented at ASCO 2013.
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
Axillary radiotherapy offers 5-year survival rates comparable to surgical dissection of the axillary lymph nodes, and a lower risk of lymphedema, according to research presented at ASCO 2013.
Continuing adjuvant tamoxifen beyond 5 years in ER+ disease reduces breast cancer recurrence, with benefit occurring primarily after year 7, found research presented at ASCO 2013.
Bevacizumab plus Chemotherapy Extends Survival in Recurrent or Persistent Stage IVB Cervical CarcinomaJune 03, 2013
Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.
Sorafenib Improves Progression-free Survival in Radioactive Iodine-refractory Metastatic Differentiated Thyroid CancerJune 03, 2013
Sorafenib represents a potential new treatment option for patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer, according to research presented at ASCO 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib